EP0042 – New Clinical Study for MDS Patients

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.


  1. SUB-TYPE OF MDS: Patients with MDS or CMML who have relapsed from or are refractory to previous therapy
  2. SEVERITY OF MDS: Intermediate, High or Very High Risk
  3. NAME OF DRUG: EP0042
  4. Aims and benefits: This Phase I/IIa study investigates different doses of the drug EP0042 to determine the dose which is safe, well tolerated and effective.
  5. Primary outcome: To identify toxicities that occur due to dosage of the study drug.

  1. Basic inclusion criteria:
    • MDS or CMML patients who have relapsed from or are refractory to previous therapy.
    • ECOG of ≤ 2
  2. Basic exclusion criteria:
    • Evidence of disease spread to the brain
    • Malignant disease other than that being treated in the study
    • Transplantation within the last 90 days or active immunosuppression for graft versus host disease
  3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
    • Dr David Taussig, London, UK, United Kingdom

If you think this information is relevant to you, please discuss it with your own physician.

Free donations by shopping

Sign-up to Download our Free Patient Handbook!

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

MDS UK Patient Support Group will use the information you provide on this form to be in touch with you and to provide updates.